Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Johnson & Johnson

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson
 
3Q Revenues: $15 billion (+13%)

3Q Earnings: $2.5 billion (-8%)

YTD Revenues: $45.1 billion (+14%)

YTD Earnings: $8.2 billion (-8%)

Comments: Worldwide pharmaceutical sales were $6.1 billion in the quarter, up 4%. Growth reflects the strong performance of Topamax, Remicade, and antipsychotic franchise, which includes Risperdal, Risperdal Consta and Invega. Earnings for the quarter include an after-tax restructuring charge of $528 million associated with a cost improvement program.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters